PhI fizzle forces Syros to spike its lead drug, triggering another rout on shares
Less than stellar Phase I results have triggered a pipeline cleanup at Syros Pharma, where one of its two lead drugs — a CDK7 inhibitor administered intravenously — is getting swapped out with an oral version.
The biotech said it maintains its belief in the CDK7 pathway for cancer, but thinks prioritizing SY-5609, which appears more selective and potent in preclinical models, is a wiser choice than holding onto an IV drug that didn’t quite embody the optimal balance between efficacy and tolerability. A human trial for SY-5609 is planned for early next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
